26 April 2011 in Cellular Microbiology
Pore‐forming toxins (PFTs) are secreted proteins that contribute to the virulence of a great variety of bacterial pathogens. They inflict one of the more disastrous damages a target cell can be exposed to: disruption of plasma membrane integrity. Since this is an ancient form of attack, which bares similarities to mechanical membrane damage, cells have evolved response pathways to these perturbations. Here, it is reported that PFTs trigger very diverse yet specific response pathways. Many are triggered by the decrease in cytoplasmic potassium, which thus emerges as a central regulator. Upon plasma membrane damage, cells activate signalling pathways aimed at restoring plasma membrane integrity and ion homeostasis. Interestingly these pathways do not require protein synthesis. Cells also trigger signalling cascades that allow them to enter a quiescent‐like state, where minimal energy is consumed while waiting for plasma membrane damage to be repaired. More specifically, protein synthesis is arrested, cytosolic constituents are recycled by autophagy and energy is stored in lipid droplets.
11 March 2021 in Nature Chemical Biology
14 July 2011 in PLOS Pathogens
Throughout evolution, one of the most ancient forms of aggression between cells or organisms has been the production of proteins or peptides affecting the permeability of the target cell membrane. This class of virulence factors includes the largest family of bacterial toxins, the pore-forming toxins (PFTs). PFTs are bistable structures that can exist in a soluble and a transmembrane state. It is unclear what drives biosynthetic folding towards the soluble state, a requirement that is essential to protect the PFT-producing cell. Here we have investigated the folding of aerolysin, produced by the human pathogen Aeromonas hydrophila, and more specifically the role of the C-terminal propeptide (CTP). By combining the predictive power of computational techniques with experimental validation using both structural and functional approaches, we show that the CTP prevents aggregation during biosynthetic folding. We identified specific residues that mediate binding of the CTP to the toxin. We show that the CTP is crucial for the control of the aerolysin activity, since it protects individual subunits from aggregation within the bacterium and later controls assembly of the quaternary pore-forming complex at the surface of the target host cell. The CTP is the first example of a C-terminal chain-linked chaperone with dual function. Many pathogenic bacteria produce proteins, called pore-forming toxins, designed to perforate the plasma membrane of target cells thus perturbing host cell integrity and functionality. It is, however, important that these toxins do not form pores in the producing bacterium. To prevent this, bacteria initially produce them in a soluble state. After being secreted by the bacterium, the toxin subsequently acquires – often through a multimerization step– the ability to insert into the membrane. Here we were interested in the mechanisms ensuring that the toxin initially folds into the soluble state. Using as an example aerolysin from the human pathogen Aeromonas hydrophila, we show that the bacterium produces the toxin with a C-terminal extension of about 45 amino acids that promotes the folding of the protein into the soluble state. We find that by mutating or removing this extension, the protein folds poorly or not at all. Addition of the peptide in trans however lead to partial recovery of activity suggesting that this extension promotes folding, and being intramolecular thus results in a very high effective concentration. In addition to this chaperone role for correctly folding the monomeric form of the toxin, the C-terminal peptide is also crucial for controlling the folding of the quaternary structure of the mature pore complex at the surface of the target host cell.
1 June 2004 in Biochemistry
15 May 2023 in Journal of Clinical Investigation
Neural differentiation, synaptic transmission, and action potential propagation depend on membrane sphingolipids, whose metabolism is tightly regulated. Mutations in the ceramide transporter CERT (CERT1), which is involved in sphingolipid biosynthesis, are associated with intellectual disability, but the pathogenic mechanism remains obscure. Here, we characterize 31 individuals with de novo missense variants in CERT1. Several variants fall into a previously uncharacterized dimeric helical domain that enables CERT homeostatic inactivation, without which sphingolipid production goes unchecked. The clinical severity reflects the degree to which CERT autoregulation is disrupted, and inhibiting CERT pharmacologically corrects morphological and motor abnormalities in a Drosophila model of the disease, which we call ceramide transporter (CerTra) syndrome. These findings uncover a central role for CERT autoregulation in the control of sphingolipid biosynthetic flux, provide unexpected insight into the structural organization of CERT, and suggest a possible therapeutic approach for patients with CerTra syndrome.